LLY vs MYO

Eli Lilly exhibits a stark divergence between explosive growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company delivers exceptional ROE (101.16%) and massive YoY revenue growth (42.6%), it trades at a significant premium to both its Graham Number ($123.85) and growth-based intrinsic value ($678.2). The current valuation is driven by high expectations for its drug pipeline, but the low deterministic health score and bearish technical trend suggest a period of consolidation or risk. Overall, it is a high-performance growth engine with concerning balance sheet efficiency metrics.

MYO exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across nearly all health metrics. Despite a high gross margin of 65.7%, the company suffers from negative revenue growth (-5.90%) and a catastrophic year-over-year EPS decline of 800%. While analyst target prices ($4.32) suggest a massive upside, this is completely decoupled from the current financial reality of negative profitability and a bearish technical trend. The company is currently a high-risk micro-cap with deteriorating fundamentals.